
Acera Surgical
Develop a portfolio of fully synthetic surgical materials that act as nano-scale scaffold for tissue regeneration.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
N/A | $5.1m | Early VC | |
Total Funding | 000k |
Acera Surgical operates in the medical device industry, focusing on the development and commercialization of advanced wound care products. The company serves healthcare providers and patients by offering solutions that address various types of wounds, including surgical, trauma, pressure, diabetic, venous, and chronic vascular ulcers. Acera's business model revolves around the production and sale of its flagship product, Restrata, a synthetic nanofabricated scaffold that is FDA cleared for wound management. This product aims to improve patient outcomes by reducing pain and enhancing healing processes. Acera generates revenue through the sale of Restrata to hospitals, clinics, and other healthcare facilities. The company is committed to advancing the science of healing and improving patient care through continuous innovation in wound care technology.
Keywords: wound care, nanofibers, Restrata, FDA cleared, healthcare, patient recovery, medical devices, synthetic scaffold, wound management, healing.